---
title: "納斯達克生物科技指數下跌 0.85%。成分股中，Lyell Immunopharma 下跌 12.87%，Summit Therapeutics Plc.下跌 11.32%，Ironwood 醫藥下跌"
description: "納斯達克生物科技指數下跌 0.85%。成分股中，Lyell Immunopharma 下跌 12.87%，Summit Therapeutics Plc.下跌 11.32%，Ironwood 醫藥下跌 9.69%。而 LENZ Therapeutics 上漲 6.84%，Insmed 上漲 7.75%，Tevogen Bio Holdings 上漲 8.06%。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/244132676.md"
published_at: "2025-06-11T20:28:36.000Z"
---

# 納斯達克生物科技指數下跌 0.85%。成分股中，Lyell Immunopharma 下跌 12.87%，Summit Therapeutics Plc.下跌 11.32%，Ironwood 醫藥下跌

> 納斯達克生物科技指數下跌 0.85%。成分股中，Lyell Immunopharma 下跌 12.87%，Summit Therapeutics Plc.下跌 11.32%，Ironwood 醫藥下跌 9.69%。而 LENZ Therapeutics 上漲 6.84%，Insmed 上漲 7.75%，Tevogen Bio Holdings 上漲 8.06%。

納斯達克生物科技指數收跌 0.85%。 成分股 Lyell Immunopharma 收跌 12.87%，Summit Therapeutics Plc.跌 11.32%，Ironwood 醫藥跌 9.69% 跌幅第三大。 LENZ Therapeutics 則收漲 6.84% 表現第三，Insmed 漲 7.75%，Tevogen Bio Holdings 也漲 8.06%。

### Related Stocks

- [LENZ.US - LENZ Therapeutics](https://longbridge.com/zh-HK/quote/LENZ.US.md)
- [INSM.US - Insmed](https://longbridge.com/zh-HK/quote/INSM.US.md)
- [LYEL.US - Lyell Immunopharma](https://longbridge.com/zh-HK/quote/LYEL.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Decreases By 16.8% | Short interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) decreased by 16.8% in January, totaling 7,260,872 shares as of J | [Link](https://longbridge.com/zh-HK/news/276071354.md) |
| Insmed (NASDAQ:INSM) CEO Sells $3,247,335.00 in Stock | Insmed CEO William Lewis sold 19,215 shares of the company's stock for $3,247,335 on January 12, reducing his ownership  | [Link](https://longbridge.com/zh-HK/news/272531097.md) |
| LENZ Therapeutics: Early VIZZ Launch, Targeted DTC Campaign, and Differentiated Presbyopia Profile Underpin Buy Rating | William Blair analyst Lachlan Hanbury Brown has maintained a Buy rating on LENZ Therapeutics due to its commercial progr | [Link](https://longbridge.com/zh-HK/news/272595337.md) |
| Insmed Incorporated Provides Revenue Guidance for the Full Year 2025 | Insmed Incorporated provided revenue guidance for the full year 2025. For the year, the company expected total revenues  | [Link](https://longbridge.com/zh-HK/news/272091006.md) |
| Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference \| INSM Stock News | Insmed Incorporated provided a business update at the 44th Annual J.P. Morgan Healthcare Conference, highlighting unaudi | [Link](https://longbridge.com/zh-HK/news/272071619.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。